Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Other: nonintervention
- Registration Number
- NCT05024539
- Lead Sponsor
- Shujun Yang
- Brief Summary
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
- Detailed Description
To analyze the real-world usage pattern, effectiveness and factors associated with the effectiveness of regorafenib in the treatment of patients with Hepatocellular Carcinoma. This retrospective, observational study included clinicopathological and follow-up data of patients with Hepatocellular Carcinoma who were treated with regorafenib from June 2017 to September 2020. Patients with incomplete data were excluded. Overall survival (OS) stratified by combination therapy with programmed cell death ligand-1 (PD-L1) inhibitors, chemotherapy and regorafenib dose was calculated by Kaplan Meier method and log rank test. R software version 4.0 was used for the analysis.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
- Must be a pathologically proven Hepatocellular Carcinoma 2. Must have been treated with regorafenib 3. Regorafenib must be used after two lines of standard antitumor therapy
- Application is less than one course of treatment with regorafenib 2. First - or second-line treatment with regorafenib 3. Patients with multiple primary cancers
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Regorafenib group nonintervention Patients were given only regorafenib orally Joint group nonintervention The patient was treated with regorafenib orally and in combination with other medications
- Primary Outcome Measures
Name Time Method The difference of overall survival in patients receiving different doses of regorafenib 2021.11-2021.12 In the real world, regorafenib was used in different dosages: 40mg,80mg,120mg,160mg,respectively. The difference in overall survival time of patients with different dosage was compared.
The difference in overall survival between the two groups calculated by Kaplan-Meier 2021.7-2021.12 Survival differences between the monotherapy and combination groups
Regorafenib in combination with other drugs 2021.7-2021.10 In the real world, regorafenib was used in combination with chemotherapy, immunotherapy or other drugs, and the frequency of occurrence of different conditions was analyzed.
- Secondary Outcome Measures
Name Time Method Survival differences among the patients with different clinical phenotypes and genotypes 2021.7-2021.10 To compare the survival of patients with Hepatocellular Carcinoma by gender, age, tumor site and other genotypes
Trial Locations
- Locations (1)
Henan cancer hosiptal
🇨🇳Zhengzhou, Henan, China